The Role of Host Genetic Variation in HIV Infection and its Manifestations

AIDS and Other Manifestations of HIV Infection

Volumn , Issue , 2004, Pages 285-302

  Kaslow, Richard A ^a   Tang, James ^b   Dorak, M Tevfik ^c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1842457975     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012764051-8/50014-7     Document Type: Chapter

References (228)

1. Pritchard JK, Rosenberg NA Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999, 65:220-228.
2. Pritchard JK, Donnelly P Case-control studies of association in structured or admixed populations. Theor Popul Biol 2001, 60:227-237.
3. Marsh SGE, Bodmer JG, Albert ED, Bodmer WF, Bontrop RE, Dupont RE, Erlich HA, Hansen JA, Mach B, Mayr WR, Parham P, Petersdorf EW, Sasazuki T, Schreuder GMT, Strominger JL, Svejgaard A, Terasaki PI Nomenclature for factors of the HLA system, 2000. Hum Immunol 2001, 62:419-468.
4. Middleton D History of DNA typing for the human MHC. Rev Immunogenet 1999, 1:135-156.
5. Borrow P, Lweicki H, Hahn BH, Shaw GH, Oldstone MBA Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 Infection. J Virol 1994, 68:6103-6110.
6. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
8. Klein MR, van Baalen C, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keep IP, Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, Miedema F Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical cohorts of HIV-infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995, 181:1365-1372.
9. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrrill M High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995, 69:5838-5842.
10. Borrow P, Lweicki H, Wei X, Horwitz M, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MBA, Shaw GH Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med 1997, 3:205-211.
11. Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O'Callaghan CA, Kalams SA, McKinney RE, Mayer K, Koup RA, Pelton SI, Burchett SK, MiIntosh K, Walker BD Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med 2000, 192:1819-1832.
12. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998.
13. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu T-M, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan LM, Dubey S, Casimiro D, Simon A, Davies M-E, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JWa, Letvin NL Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 486-492.
14. Schmitz JE, Kuroda MJ, Veazey RS, Seth A, Taylor WM, Nickerson CE, Lifton MA, Dailey PJ, Forman MA, Racz P, Tenner-Racz K, Letvin NL Simian immunodeficiency virus (SIV)-specific CTL are present in large numbers in livers of SIV-infected rhesus monkeys. J Immunol 2000, 164:6015-6019.
15. Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, DiMascio M, Perelson AS, Marx PA, Ho DD, Kostrikis LG, Connor RI T-cell depletion on virus replication in rhesus macaques immunized with a live, attenuated siminan immunodeficiency virusvaccine. J Exp Med 2000, 191:1921-1932.
16. Kaslow RA, McNicholl JM Genetic determinants of HIV-1 infection and its manifestations. Proc Assoc Am Physicians 1999, 111:299-307.
17. McNicholl JM, Cuenco KT Host genes and infectious diseases-HIV, other pathogens, and a public health perspective. Am J Prevent Med 1999, 16:141-154.
18. O'Brien SJ, Nelson GW, Winkler CA, Smith MW Polygenic and multifactorial disease gene association in man: lessons from AIDS. Annu Rev Genet 2000, 34:563-591.
19. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-D32, CCR2-64I and SDF-1 3' A alleles on HIV disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001, 135:782-795.
20. Tang J, Costello C, Keet IPM, Rivers C, LeBlanc S, Karita E, Allen S, Kaslow RA HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999, 15:317-324.
21. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ HLA and HIV-1: Heterozygosity advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748-1752.
22. Keet IP, Tang J, Klein MR, LeBlanc S, Enger C, Rivers C, Apple RJ, Mann D, Goedert JJ, Miedema F, Kaslow RA Consistent associations of HLA class I and class II and transporter gene products with progression of human immunodeficiency virus-1 infection in homosexual men. J Infect Dis 1999, 180:299-309.
23. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJG, Morrison H, Jones M, Simmonds P HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988, 1(8596):1185-1188.
24. Kaslow RA, Duquesnoy R, VanRaden M, Kingsley L, Marrari M, Su S, Saah AJ, Detels R, Phair JP, Rinaldo CR Combinations of A1, Cw7, B8, DR3 HLA antigens associated with rapid decline of T-helper lymphocytes in HIV-1 infected homosexual men: a report from the Multicenter AIDS Cohort Study. Lancet 1990, 335:927-930.
25. Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, Zeleniuch-Jacquotte A, Winchester R HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Def Syndr 1992, 5:37-45.
26. McNeil AJ, Yap PL, Gore SM, Brettle RP, McColl M, Wyld R, Davidson S, Weightman R, Richardson AM, Robertson JR Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Quart J Med 1996, 89:177-185.
27. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SL, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405-411.
28. Keet IPM, Klein MR, Just JJ, Kaslow RA The role of host genetics in the natural history of HIV-1 infection: the needles in the haystack. AIDS 1996, 10(Suppl. A):S59-S67.
29. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, Schachter F, Zagury D, Rappaport J, Winkler C, Nelson GW, Zagury JF New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999, 162:6942-6946.
30. Costello C, Tang J, Rivers C, Karita E, Meizen-Derr J, Allen S, Kaslow RA HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS 1999, 13:1990-1991.
31. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, Riviere Y, Charron D, Costagliola D Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 1999, 93:936-941.
32. Gao F, Vidal N, Li Y, Trask SA, Chen Y, Kostrikis LG, Ho DD, Kim J, Oh MD, Choe K, Salminen M, Robertson DL, Shaw GM, Hahn BH, Peeters M Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. AIDS Res Hum Retroviruses 2001, 17:675-688.
33. Tang J, Tang S, Lobashevsky E, Myracle AD, Fideli U, Aldrovandi G, Allen S, Musonda R, Kaslow RA Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. J Virol 2002, in press.
34. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000, 97:2709-2714.
35. Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ, Kiama P, Peto T, Plummer FA, McMichael AJ, Rowland-Jones SL Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS 2002, 16:961-972.
36. Balla-Jhagjhoorsingh SS, Koopman G, Mooij P, Haaksman TGM, Teeuwsen VJP, Bontrop RE, Neeney JL Conserved CTL epitope shared between HIV-infected human long-term survivors and chimpanzees. J Immunol 1999, 162:2308-2314.
37. Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, Korber B, Vermund SH, Kaslow RA Host genetic profiles predict virological and immunological control of human immunodeficiency virus type 1 infection in adolescents. AIDS 2002, in press.
38. Tang J, Tang S, Rivers CA, Dorak MT, Penman-Aguilar A, Aldrovandi G, Allen S, Karita E, Musonda R, Kaslow RA Distinct and evolving HLA class I profiles in native Africans with high prevalence of HIV/AIDS. HLA 2002: Immunobiology of the Human MHC 2003, 2. IHWG Press, Seattle. J. Hansen, B. Dupont (Eds.).
39. Carrington M, Nelson G, O'Brien SJ Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunol Lett 2001, 79:131-140.
40. Ioannidis JP, Goedert JJ, McQueen PG, Enger C, Kaslow RA Comparison of viral load and human leukocyte antigen statistical and neural network predictive models for the rate of HIV-1 disease progression across two cohorts of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:129-136.
41. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda G, Catano G, Cabrera S, McBride M, Cao X-H, Merrill G, O'Connell P, Bowden DW, Frredman BI, Anderson SA, Walters EA, Evans JS, Stephan KT, Clark RA, Tyagi S, Ahuja SS, Dolan MJ, Ahuja SK Race-specific HIV-1 disease modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999, 96:12004-12009.
42. Tang J, Shelton B, Makhatadze NJ, Zhang Y, Schaen M, Louie L, Goedert JJ, Seaburg EC, Margolick JB, Mellors J, Kaslow RA Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002, 76:662-672.
43. Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, Shearer GM Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV contaminated body fluids. J Clin Invest 1995, 96:867-876.
44. Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, Blanchard T, Ariyoshi K, Oyugi J, Ngugi E, Bwayo J, MacDonald KS, McMichael AJ, Plummer FA Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998, 102:1758-1765.
45. Rohowsky-Kochan C, Skurnick J, Molinaro D, Louria D HLA antigens associated with susceptibility/resistance to HIV-1 infection. Hum Immunol 1998, 59:802-815.
46. Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, Robb ML, Rinkaew M, Birx DL, Khamboonruang C, Zimmerman PA, Nelson KE, Natpratan C Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. J Infect Dis 1999, 179:59-67. Chiang Mai HEPS Working Group.
47. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, Njagi E, MacDonald KS, Bwayo JJ, McMichael AJ, Rowland-Jones SL HIV-1-specific mucosal CD8(+) lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000, 164:1602-1611.
48. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJD, Ball TB, Oyugi J, Njagi E, Gaur LK, Brunham RC, Wade J, Luscher MA, Hrausa P, Rowland-Jones S, Ngugi E, Bwayo JJ, Plummer FA Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2000, 181:1581-1589.
49. Rowland-Jones S, Nixon D, Aldhous M, Gotch F, Ariyoshi K, Hallam N, Kroll JS, Froebel K, McMichael A HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993, 341:860-861.
50. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Corrah A, Takiguchi M, Schultz T, McMichael A, White H HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995, 1:59-64.
51. Rowland-Jones SL, Dong T, Dorrell L, Ogg G, Hansasuta P, Krausa P, Kimani J, Sabally S, Ariyoshi K, Oyugi J, MacDonald KS, Bwayo J, Whittle H, Plummer FA, McMichael AJ Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunol Lett 1999, 66:9-14.
52. Bienzle D, MacDonald KS, Smaill FM, Kovacs C, Baqi M, Courssaris B, Luscher MA, Walmsley SL, Rosenthal KL Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partners. J Infect Dis 2000, 182:123-132.
53. Lockett SF, Robertson JR, Brettle RP, Yap PL, Middleton D, Leigh Brown AJ Mismatched human leukocyte antigen alleles protect against heterosexual HIV transmission. J Acquir Immune Defic Syndr 2001, 27:277-280.
54. Dorak MT, Tang J, Westfall A, Zulu I, Leakeas CL, Schaen MM, Kancheya N, Allen S, Kaslow RA HLA class I effects on transmission of HIV-1C in heterosexual Zambian couples: Risk of concordance at HLA-B. AIDS 2002 2002, Barcerola.
55. Beretta A, Furci L, Burastero S, Cosma A, Dinelli ME, Lopalco L, DeSantis C, Tambussi G, Carrow E, Sabbatani S, Clerici M, Lazzarin A, Siccardi AG HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. Immunol Lett 1996, 51:39-43.
56. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, Clerici M HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997, 3:1250-1257.
57. McKenna SL, Muyinda GK, Roth D, Mwali M, Ng'andu N, Myrick A, Luo C, Priddy FH, Hall VM, von Lieven AA, Sabatino JR, Mark K, Allen SA Rapid HIV testing and counseling for voluntary testing centers in Africa. AIDS 1997, 11(Suppl. 1):S103-S110.
58. Fideli U.S., Allen S, Musunda R, Trask S, Hahn B, Mulenga J, Kasolo FC, Vermund SH, Adrovandi G Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 (HIV-1) in Africa. AIDS Res Hum Retroviruses 2001, 17:901-910.
59. Trask SA, Derdeyn CA, Fideli U, Chen Y, Meleth S, Kasolo F, Musonda R, Hunter E, Gao F, Allen S, Hahn BH Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol 2002, 76:397-405.
60. MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, Njenga S, Oyug J, Ndinya-Achola J, Barber BH, Bwayo JJ, Plummer FA The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001, 183:503-506.
61. Liu C, Carrington M, Kaslow R, Gao X, Rinaldo C, Jacobson L, Margolick J, Phair J, O'Brien S, Detels R The association of polymorphisms in HLA class I and TAP genes with resistance to HIV-1 infection. 9th Conference on Retroviruses and Opportunistic Infections 2002, Seattle, WA.
62. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, Rostron T, Njagi E, Bwayo JJ, MacDonald KS, McMichael AJ, Plummer FA Late seroconversion in HIV-resistant Nairobi prostitutes despite pre- existing HIV-specific CD8 + responses. J Clin Invest 2001, 107:341-349.
63. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, Kiama P, Rutherford J, Njagi E, Mwangi F, Rostron T, Onyango J, Oyugi J, MacDonald KS, Bwayo JJ, Plummer FA New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001, 79:3-13.
64. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, O'Brien S, Carrington M Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001, 344:1668-1675.
65. MacDonald KS, Embree J, Njenga S, Nagelkerke NJD, Ngatia I, Mohammed Z, Barber BH, Ndinya-Achola J, Bwayo J, Plummer FA Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 infection. J Infect Dis 1998, 177:551-556.
66. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
67. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002, 359:1121-1122.
68. Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, Mulligan MM, Desrosiers RC Induction of vigorous cytotoxic T lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997, 17?:7711-7718.
69. Seth A, Ourmanov I, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Wyatt L, Carroll M, Moss B, Venzon D, Letvin NL, Hirsch VM Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primers for an anemnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 2000, 74:2502-2509.
70. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia (see comments). Nature 2000, 407:386-390.
71. Mulligan MJ, Webber J Human trials of HIV-1 vaccines. AIDS 1999, 13(Suppl. A):S105-S112.
72. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J Expt Med 1992, 175:495-502.
73. Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev 1999, 170:151-172.
74. Hayney MS, Poland GA, Dimanlig P, Schaid DJ, Jacobson RM, Lipsky JJ Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine 1997, 15:3-6.
75. Gorse GJ, Patel GB, Newman FK, Mandava M, Belshe RB Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network. Vaccine 1995, 13:1170-1179.
76. McElrath MJ, Siliciano RF, Weinhold KJ HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res Human Retroviruses 1997, 13:211-216.
77. Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998, 12:2407-2415. NIAID AIDS Vaccine Evaluation Group.
78. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori G, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia JA A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999, 180:290-298.
79. Kaslow RA, Rivers CR, Tang J, Bender TJ, Goepfert PA, El Habib R, Weinhold K, Mulligan MJ Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001, 75:8681-8689. NIAID AIDS Vaccine Evaluation Group.
80. Tang J, Freedman DO, Allen S, Karita E, Musonda R, Braga C, Margolick J, Kaslow RA TAP1 polymorphisms in several human ethnic groups: characteristics, evolution, and genotyping strategies. Hum Immunol 2001, 62:256-268.
81. Tang J, Freedman DO, Allen SA, Karita E, Musonda R, Braga C, Jamieson BD, Louie L, Kaslow RA Genotyping TAP2 variants in North American Caucasians, Brazilians, and Africans. Genes Immun 2001, 2:32-40.
82. Yan G, Shi L, Faustman D Novel splicing of the human MHC-encoded peptide transporter confers unique properties. J Immunol 1999, 162:852-859.
83. Powis SH, Rosenberg WM, Hall M, Mockridge I, Tonks S, Ivinson A, Ciclitira PJ, Jewell DP, Lanchbury JS, Bell JI TAP1 and TAP2 polymorphism in celiac disease. Immunogenetics 1993, 38:345-350.
84. Powis SH, Cooper MD, Trowsdale J, Zhu Z-B, Volanakis JE Major histocompatibility haplotypes associated with immunoglobulin-A deficient and common variable immunodeficiency: Analysis of the peptide transporter genes TAP1 and TAP2. Tiss Antig 1994, 43:261-265.
85. Szafer F, Oksenberg JR, Steinman L New allelic polymorphisms in TAP genes. Immunogenetics 1994, 39:374.
86. Moins-Teissernc H, Bobrynina V, Loiseau P, Charron D New polymorphisms within the human TAP1 and TAP2 coding regions. Immunogenetics 1995, 42:308.
87. Shi L, Yan G, Fu Y, Ma L, Penfornis A, Faustman D Human TAP1 polymorphisms detected by denaturing gradient gel electrophoresis. Tiss Antig 1997, 49:421-426.
88. Rau H, Nicolay A, Usadel KH, Finke R, Donner H, Walfish PG, Badenhoop K Polymorphisms of TAP1 and TAP2 genes in Graves' disease. Tiss Antig 1997, 49:16-22.
89. Takeuchi F, Nakano K, Matsuta K, Takizawa K, Nabeta H, Kuwata S, Ito K Polymorphism of TAP1 and TAP2 in Japanese patients with rheumatoid arthritis. Tiss Antig 1997, 49:280-282.
90. Armandola EA, Momburg F, Nijenhuis M, Bulbuc N, Fruh K, Hammerling GJ A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Eur J Immunol 1996, 26:1748-1755.
91. Quadri SA, Singal DP Peptide transport in human lymphoblastoid and tumor cells: effect of transporter associated with antigen presentation (TAP) polymorphism. Immunol Lett 1998, 61:25-31.
92. Detels R, Mann D, Carrington M, Hennessey K, Wu Z, Hirji KF, Wiley D, Visscher BR, Giorgi JV Resistance to HIV infection may be genetically mediated. AIDS 1996, 10:102-104.
93. Douek D, Brenchley J, Betts M, Ambrozak D, Hill B, Okamoto Y, Casazza J, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price D, Connors M, Koup R HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.
94. Douek DC, Betts MR, Brenchley JM, Hill BJ, Ambrozak DR, Ngai KL, Karandikar NJ, Casazza JP, Koup RA A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J Immunol 2002, 168:3099-3104.
95. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
96. Beck S, Kelly A, Radley E, Khurshid F, Alderton RP, Trowsdale J DNA sequence analysis of 66 kb of the human MHC class II region encoding a cluster of genes for antigen processing. J Mol Biol 1992, 228:433-441.
97. Beck S, Abdulla S, Alderton RP, Glynne RJ, Gut IG, Hosking LK, Jackson A, Kelly A, Newell WR, Sanseau P, Radley E, Thorpe KL, Trowsdale J Evolutionary dynamics of non-coding sequences within the class II region of the human MHC. J Mol Biol 1996, 255:1-13.
98. Andersson L, Mikko S Generation of MHC class II diversity by intra- and intergenic recombination. Immunol Rev 1995, 143:6-12.
99. Itescu S, Brancato LJ, Winchester R A sicca syndrome in HIV infection: association with HLA-DR5 and CD8 lymphocytosis. Lancet 1989, 2(8661):466-468.
100. Itescu S, Rose S, Dwyer E, Winchester R Certain HLA-DR5 and -DR6 major histocompatibility complex class II alleles are associated with a CD8 lymphocytic host response to human immunodeficiency virus type 1 characterized by low lymphocyte viral strain heterogeneity and slow disease progression. Proc Natl Acad Sci USA 1995, 91:11472-11476.
101. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999, 354:2119-2124.
102. Cramp ME, Rossol S, Cholkshi S, Carucci P, Williams R, Naoumov NV Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118:346-355.
103. Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, Sette A, Massari M, Southwood S, Bertoni R, Valli A, Fiaccadori F, Ferrari C Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 1999, 30:1088-1098.
104. Chen Y, Winchester R, Korber B, Gagliano J, Bryson Y, Hutto C, Martin N, McSherry G, Petru A, Wara D, Ammann A Influence of HLA alleles on the rate of progression of vertically transmitted HIV infection in children: association of several HLA-DR13 alleles with long-term survivorship and the potential association of HLA-A*2301 with rapid progression to AIDS. Long-Term Survivor Study. Hum Immunol 1997, 55:154-162.
105. LeBlanc SB, Naik EG, Jacobson L, Kaslow RA Association of DRB1*1501 with disseminated Mycobacterium avium complex infection in North American AIDS patients. Tissue Antigens 2000, 55:17-23.
106. Graziosi C, Pantaleo G The multi-faceted personality of HIV. Nat Med 1997, 3:1318-1320.
107. Rollins BJ, Morton CC, Ledbetter DH, Eddy RL, Shows TB Assignment of the human small inducible cytokine A2 gene, SCYA2 (encoding JE or MCP-1), to 17q11.2-12: evolutionary relatedness of cytokines clustered at the same locus. Genomics 1991, 10:489-492.
108. Naruse K, Ueno M, Satoh T, Nomiyama H, Tei H, Takeda M, Ledbetter DH, Coillie EV, Opdenakker G, Gunge N, Sakaki Y, Iio M, Miura R A YAC contig of the human CC chemokine genes clustered on chromosome 17q11.2. Genomics 1996, 34:236-240.
109. Modi WS, Chen ZQ Localization of the human CXC chemokine subfamily on the long arm of chromosome 4 using radiation hybrids. Genomics 1998, 47:136-139.
110. Maho A, Carter A, Bensimon A, Vassart G, Parmentier M Physical mapping of the CC-chemokine gene cluster on the human 17q11. 2 region. Genomics 1999, 59:213-223.
111. Nomiyama H, Fukuda S, Iio M, Tanase S, Miura R, Yoshie O Organization of the chemokine gene cluster on human chromosome 17q11.2 containing the genes for CC chemokine MPIF-1, HCC-2, HCC-1, LEC, and RANTES. J Interferon Cytokine Res 1999, 19:227-234.
112. Erdel M, Theurl M, Meyer M, Duba HC, Utermann G, Werner-Felmayer G High-resolution mapping of the human 4q21 and the mouse 5E3 SCYB chemokine cluster by fiber-fluorescence in situ hybridization. Immunogenetics 2001, 53:611-615.
113. Nomiyama H, Mera A, Ohneda O, Miura R, Suda T, Yoshie O Organization of the chemokine genes in the human and mouse major clusters of CC and CXC chemokines: diversification between the two species. Genes Immun 2001, 2:110-113.
114. Ahuja SK, Ozcelik T, Milatovitch A, Francke U, Murphy PM Molecular evolution of the human interleukin-8 receptor gene cluster. Nat Genet 1992, 2:31-36.
115. Combadiere C, Ahuja SK, Murphy PM Cloning, chromosomal localization, and RNA expression of a human beta chemokine receptor-like gene. DNA Cell Biol 1995, 14:673-680.
116. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996, 271:17161-17166.
117. Samson M, Soularue P, Vassart G, Parmentier M The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3. Genomics 1996, 36:522-526.
118. Daugherty BL, Springer MS The beta-chemokine receptor genes CCR1 (CMKBR1), CCR2 (CMKBR2), and CCR3 (CMKBR3) cluster within 285 kb on human chromosome 3p21. Genomics 1997, 41:294-295.
119. Maho A, Bensimon A, Vassart G, Parmentier M Mapping of the CCXCR1, CX3CR1, CCBP2 and CCR9 genes to the CCR cluster within the 3p21.3 region of the human genome. Cytogenet Cell Genet 1999, 87:265-268.
120. Paxton WA, Martin SR, Tse D, O'Brien TR, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med 1996, 2:412-417.
121. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, Mackay CR, Koup RA Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 1998, 244:66-73.
122. Paxton WA, Kang S, Liu R, Landau NR, Gingeras TR, Wu LJ, Mackay CR, Koup RA HIV-1 infectability of CD4(+) lymphocytes with relation to beta-chemokines and the CCR5 coreceptor. Immunol Lett 1999, 66:71-75.
123. Paxton WA, Neumann AU, Kang S, Deutch L, Brown RC, Koup RA, Wolinsky SM RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis 2001, 183:1678-1681.
124. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA A new classification for HIV-1. Nature 1998, 391:240.
125. Doranz BJ, Rucker J, Yanjie Y, Symth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
126. Berger EA HIV entry and tropism: the chemokine receptor connection. AIDS 1997, 11:S3-S16.
127. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, Goldsmith MA Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science 1996, 274:1924-1926.
128. Deng H, Liu R, Ellmeir W, Choe S, Unutmaz D, Burkhart M, DiMarzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
129. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
130. Ayehunie S, Garcia-Zepeda EA, Hoxie JA, Horuk R, Kupper TS, Luster AD, Ruprecht RM Human immunodeficiency virus-1 entry into purified blood dendritic cells through CC and CXC chemokine coreceptors. Blood 1997, 90:1379-1386.
131. Bjomdal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997, 71:7478-7487.
132. Berger EA, Murphy PM, Farber JM Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700.
133. Tang J, Kaslow RA Chemokine receptor and ligand polymorphisms in HIV infection. Susceptibility to Infectious Diseases: The Importance of Host Genetics 2002, in press, Cambridge University Press, Cambridge. 1st ed. R. Bellamy (Ed.).
134. Margolis LB, Glushakova S, Grivel JC, Murphy PM Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines. J Clin Invest 1998, 101:1876-1880.
135. Tartakovsky B, Turner D, Vardinon N, Burke M, Yust I Increased intracellular accumulation of macrophage inflammatory protein 1beta and its decreased secretion correlate with advanced HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:420-422.
136. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, Gallo RC Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999, 96:11986-11991.
137. McKenzie SW, Dallalio G, North M, Frame P, Means RT Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996, 10:F29-F33.
138. Schmidtmayerova H, Nottet HS, Nuovo G, Raabe T, Flanagan CR, Dubrovsky L, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruit-ment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci USA 1996, 93:700-704.
139. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo R, et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 1997, 278:695-698.
140. Canque B, Bakri Y, Camus S, Yagello M, Benjouad A, Gluckman JC The susceptibility to X4 and R5 human immunodeficiency virus-1 strains of dendritic cells derived in vitro from CD34(+) hematopoietic progenitor cells is primarily determined by their maturation stage. Blood 1999, 93:3866-3875.
141. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5'-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem 1997, 272:30662-30671.
142. Zhang YJ, Dragic T, Cao Y, Kostrikis L, Kwon DS, Littman DR, KewalRamani VN, Moore JP Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol 1998, 72:9337-9344.
143. Mummidi S, Bamshad M, Ahuja SS, Gonzalez E, Feuillet PM, Begum K, Galvis MC, Kostecki V, Valente AJ, Murthy KK, Haro L, Dolan MJ, Allan JS, Ahuja SK Evolution of human and nonhuman primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. J Biol Chem 2000, 275:18946-18961.
144. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
145. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, Anderson SA, Walter EA, Stephan KT, Hammer MF, Mangano A, Sen L, Clark RA, Ahuja SS, Dolan MJ, Ahuja SK Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: Impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001, 98:5199-5204.
146. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Franscisco Cohort Study, ALIVE Study, O'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a common deletion allele of the chemokine receptor 5 structural gene. Science 1996, 273:1856-1862.
147. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
148. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
149. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, Cohen O, Rubbert A, Lam G, Vaccarezza M, Kennedy PE, Kumaraswami V, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB, Murphy PM Inherited resistance of HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997, 3:23-36.
150. Barroga CF, Raskino C, Fangon MC, Palumbo PE, Baker CJ, Englund JA, Spector SA The CCR5D32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment. J Infect Dis 2000, 182:413-419.
151. Rizzardi GP, Morawetz RA, Vicenzi E, Ghezzi S, Poli G, Lazzarin A, Pantaleo G The Swiss HIV Cohort. CCR2 polymorphism and HIV disease. Nat Med 1998, 4:252-253.
152. Buseyne P, Janvier G, Teglas JP, Ivanoff S, Burgard M, Bui E, Mayauk MJ, Blanche S, Rouzioux C, Riviere Y Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age. J Infect Dis 1998, 178:1019-1023.
153. Valdez H, Purvis SF, Lederman MM, Fillingame M, Zimmerman PA Association of the CCR5D32 mutation with improved response to antiretroviral therapy. JAMA 1999, 282:734.
154. O'Brien TR, McDermott DH, Ioannidis JP, Carrington M, Murphy PM, Havlir DV, Richman DD Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000, 14:821-826.
155. Guerin S, Meyer L, Theodorou I, Boufassa F, Magierowska M, Goujard C, Rouzioux C, Debre P, Delfraissy JF CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2000, 14:2788-2790.
156. Easterbrook PJ, Rostron T, Ives N, Troop M, Gazzard BG, Rowland-Jones SL Chemokine receptor polymorphisms and human immunodeficiency virus disease progression. J Infect Dis 1999, 180:1096-1105.
157. Ferbas J, Giorgi JV, Amini S, Grovit-Ferbas K, Wiley DJ, Detels R, Plaeger S Antigen-specific production of RANTES, macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta in vitro is a correlate of reduced human immunodeficiency virus burden in vivo. J Infect Dis 2000, 182:1247-1250.
158. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Metais P, Montagnier L, Virelizier J-L, Arenzana-Seisdedos F, Beretta A HIV-1 resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351:14-18.
159. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow RA, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner W, HGDS, MHCS, MACS, SFCC, ALIVE-Study, O'Brien SJ Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997, 277:959-965.
160. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Ho DD, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998, 4:350-353.
161. Anzala AO, Ball TB, Rostron T, O'Brien SJ, Plummer FA, Rowland-Jones SL University of Nairobi Collaboration for HIV Research. CCR2-641 allele and genotype association with delayed AIDS progression in African women. Lancet 1998, 351:1632-1633.
162. Michael NL, Louie L, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang C-E, Sherppard HW The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997, 3:1160-1162.
163. Eugen-Olsen J, Iversen AK, Benfield TL, Koppelhus U, Garred P Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:110-116.
164. Hendel H, Henon N, Lebuanec H, Lachgar A, Poncelet H, Caillat-Zucman S, Winkler CA, Smith MW, Kenefic L, O'Brien S, Lu W, Andrieu JM, Zagury D, Schachter F, Rappaport J, Zagury JF Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:381-386.
165. Viscocomandini U, Hultgren C, Brostrom C, Birk M, Kim S, Sallberg M Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses. Clin Diagn Lab Immunol 1998, 5:463-466.
166. Schinkel J, Langendam MW, Coutinho RA, Krol A, Brouwer M, Schuitemaker H No evidence for an effect of the CCR5 D32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis 1999, 179:825-831.
167. Tang J, Rivers C, Karita E, Costello C, Allen S, Fultz PN, Schoenbaum EE, Kaslow RA Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable association with HIV-1 disease progression. Genes Immun 1999, 1:20-27.
168. Frade JMR, Llorente M, Mellado M, Alcami J, Gutierrez-Ramos JC, Zaballos A, Real G, Martinez AC The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. Journal of Clinical Investigation 1997, 100:497-502.
169. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, The Multicenter AIDS Cohort Study, Murphy PM CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998, 352:866-870.
170. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S, Goedert JJ, O'Rien TS, Hilgartner MW, Vlahov D, O'Brien S, Carrington M Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282:1907-1911.
171. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tryon V, Clark RA, Dolan MJ, Ahuja SK Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998, 4:786-793.
172. An P, Martin MP, Nelson GW, Carrington M, Smith MW, Gong K, Vlahov D, O'Brien SJ, Winkler CA Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 2000, 14:2117-2122.
173. Mangano A, Gonzalez E, Dhanda R, Catano G, Bamshad M, Bock A, Duggirala R, Williams K, Mummidi S, Clark RA, Ahuja SS, Dolan MJ, Bologna R, Sen L, Ahuja SK, Sen L Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001, 183:1574-1585.
174. Tang J, Wilson CM, Schaen M, Myracle AD, Douglas SD, Kaslow RA CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. AIDS Res Hum Retroviruses 2002, 18:403-412.
175. D'Aquila RT, Sutton L, Savara A, Hughes MD, Johnson VA NIAID AIDS Clinical Trials Group Protocol 241 Virology Team. CCR5/D(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. J Infect Dis 1998, 177:1549-1553.
176. Liu HL, Chao D, Nakayama EE, Taguchi H, Goto M, Xin XM, Takamatsu J, Saito H, Ishikawa Y, Akaza T, Juji T, Takebe Y, Ohishi T, Fukutake K, Maruyama Y, Yashiki SJ, Sonoda S, Nakamura T, Nagai Y, Iwamoto A, Shioda T Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999, 96:4581-4585.
177. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, Boatin BA, Leitman SF, Detels R, Hajeer AH, Murphy PM Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000, 14:2671-2678.
178. Philpott S, Burger H, Charbonneau T, Grimson R, Vermund SH, Visosky A, Nachman S, Kovacs A, Tropper P, Frey H, Weiser B CCR5 genotype and resistance to vertical transmission of HIV-1. J Acquir Immune Defic Syndr 1999, 21:189-193.
179. Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbind S, Koblin BA, Seage GR HIV Network for Prevention Trials Vaccine Preparedeness Protocol Team. Homozygous and heterozygous CCR5-D32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001, 27:472-481.
180. Kostrikis LG, Neumann AU, Thomson B, Korber BT, McHardy P, Karanicolas R, Deutsch L, Huang Y, Lew JF, McIntosh K, Pollack H, Borkowsky W, Spiegel HM, Palumbo P, Oleske J, Bardeguez A, Luzuriaga K, Sullivan J, Wolinsky SM, Koup RA, Ho DD, Moore JP A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol 1999, 73:10264-10271.
181. Mangano A, Kopka J, Batalla M, Bologna R, Sen L Protective effect of CCR2-64I and not of CCR5-delta32 and SDF1-3'A in pediatric HIV-1 infection. J Acquir Immune Defic Syndr 2000, 23:52-57.
182. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O'Brien SJ Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998, 279:389-393.
183. van Rij RP, Proersen S, Goudsmit J, Coutinho RA, Schuitemaker H The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998, 12:F85-F90.
184. Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood 1999, 93:1838-1842.
185. Brambilla A, Rizzardi GP, Veglia F, Sheppard HW, Lazzarin A, Poli G, Pantaleo G, Michael NL, Vicenzi E The SDF1-3'A genotype associates with accelerated time to death from AIDS diagnosis. Role of CD4+ T-cell counts. 7th Conference on Retroviruses and Opportunistic Infections 2000, 234.
186. Lathey J, Tierney C, Chang S, D'Aquilla R, Hammer S, Katzenstein D Homozygous mutations in 3'A SDF-1 are associated with more rapid disease progression. 7th Conference on Retroviruses and Opportunistic Infections 2000, 234.
187. Tresoldi E, Romiti ML, Boniotto M, Crovella S, Salvatori F, Palomba E, Pastore A, Cancrini C, de Martino M, Plebani A, Castelli G, Rossi P, Tovo PA, Amoroso A, Scarlatti G Prognostic value of the stromal cell-derived factor 1 3'A mutation in pediatric human immunodeficiency virus type 1 infection. J Infect Dis 2002, 185:696-700.
188. Mazzucchelli R, Corvasce S, Violin M, Riva C, Bianchi R, Deho L, Velleca R, Cibella J, Bada M, Moroni M, Galli M, Balotta C Role of CCR5, CCR2 and SDF-1 gene polymorphisms in a population of HIV-1 infected individuals. J Biol Regul Homeost Agents 2001, 15:265-271.
189. Sei S, Boler AM, Nguyen GT, Stewart SK, Yang QE, Edgerly M, Wood LV, Brouwers P, Venzon DJ Protective effect of CCR5 D32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection. AIDS 2001, 15:1343-1352.
190. John GC, Rousseau C, Dong T, Rowland-Jones S, Nduati R, Mbori-Ngacha D, Rostron T, Kreiss JK, Richardson BA, Overbaugh J Maternal SDF1 3'A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. J Virol 2000, 74:5736-5739.
191. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P, Theodorou I, Combadiere C Rapid progression to AIDS in HIV + individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000, 287:2274-2277.
192. McDermott DH, Colla JS, Kleeberger CA, Plankey M, Rosenberg PS, Smith ED, Zimmerman PA, Combadiere C, Leitman SF, Kaslow RA, Goedert JJ, Berger EA, O'Brien TR, Murphy PM Genetic polymorphism in CX3CR1 and risk of HIV disease. Science 2000, 290:2031.
193. Hendel H, Winkler C, An P, Roemer-Binns E, Nelson G, Haumont P, O'Brien S, Khalilli K, Zagury D, Rappaport J, Zagury JF Validation of genetic case-control studies in AIDS and application to the CX3CR1 polymorphism. J Acquir Immune Defic Syndr 2001, 26:507-511.
194. Dean M, Jacobson LP, McFarlane G, Margolick JB, Jenkins FJ, Howard OM, Dong HF, Goedert JJ, Buchbinder S, Gomperts E, Vlahov D, Oppenheim JJ, O'Brien SJ, Carrington M Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999, 59:3561-3564.
195. Sei S, O'Neill DP, Stewart SK, Yang Q, Kumagai M, Boler AM, Adde MA, Zwerski SL, Wood LV, Venzon DJ, Magrath IT Increased level of stromal cell-derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma. Cancer Res 2001, 61:5028-5037.
196. Wanidworanun C, Strober W Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 1993, 151:6853-6861.
197. Brown CC, Poli G, Lubaki N, St.Louis M, Davachi F, Musey L, Manzila T, Kovacs A, Quinn TC, Fauci AS Elevated levels of tumor necrosis factor-alpha in Zairian neonate plasmas: implications for perinatal infection with the human immunodeficiency virus. J Infect Dis 1994, 169:975-980.
198. Rizzardi GP, Barcellini W, Tambussi G, Lillo F, Malnati M, Perrin L, Lazzarin A Plasma levels of soluble CD30, tumor necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 1996, 10:F45-F50.
199. Wahl SM, Greenwellwild T, Peng G, Haledonze P, Doherty TM, Mizel D, Orenstein JM Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc Natl Acad Sci USA 1998, 95:12574-12579.
200. Aukrust P, Muller F, Lien E, Nordoy I, Liabakk N-B, Kvale D, Espevik T, Froland SS Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999, 179:74-82.
201. Lawn SD, Shattock RJ, Acheampong JW, Lal RB, Folks TM, Griffin GE, Butera ST Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. AIDS 1999, 13:2231-2237.
202. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147:3815-3822.
203. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991, 146:3444-3451.
204. Kundu N, Fulton AM Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 1997, 180:55-61.
205. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997, 71:630-637.
206. Tsuruma T, Yagihashi A, Torigoe T, Sato N, Kikuchi K, Watanabe N, Hirata K Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells. Cell Immunol 1998, 184:121-128.
207. Houle M, Thivierge M, Le Gouill C, Stankova J, Rola-Pleszczynski M IL-10 up-regulates CCR5 gene expression in human monocytes. Inflammation 1999, 23:241-251.
208. Allen RD Polymorphisms of the human TNF-a promoter-random variation or functional diversity?. Mol Immunol 1999, 36:1017-1027.
209. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LBA, Duff GW An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8 and DR3 alleles. J Exp Med 1993, 177:557-560.
210. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 1995, 42:501-504.
211. Weissensteiner T, Lanchbury JS TNFB polymorphisms characterize three lineages of TNF region microsatellite haplotypes. Immunogenetics 1997, 47:6-16.
212. Kroeger KM, Carville KS, Abraham LJ The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997, 34:391-399.
213. Brinkman BMN, Zuijdgeest D, Kaijzel EL, Breedveld FC, Verweij CL Relevance of the TNF-alpha-308 promoter polymorphism in TNF-alpha gene regulation. J Inflamm 1996, 46:32-41.
214. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
215. Khoo SH, Pepper L, Snowden N, Majeer AH, Vallely P, Wilkins EGL, Mandal BK, Ollier ER Tumor necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS 1997, 11:423-428.
216. Brinkman BMN, Keet IPM, Miedema F, Verweij CL, Klein MR Polymorphisms within the human tumor necrosis factor-alpha region in human immunodeficiency virus type 1-seropositive persons. J Infect Dis 1997, 175:188-190.
217. Knuchel MC, Spira TJ, Neumann AU, Xiao L, Rudolph DL, Phair J, Wolinsky SM, Koup RA, Cohen OJ, Folks TM, Lal RB Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression. AIDS Res Hum Retrovir 1998, 14:305-309.
218. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
219. Eskdale J, Keijsers V, Huizinga T, Gallagher G Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Gene Immun 1999, 1:151-155.
220. Shin H, Winkler C, Stevens JC, Bream J, Young H, Goedert JJ, O'Brien TR, Vlahov D, Buchbinder S, Giorgi J, Rinaldo C, Donfield S, Willoughby A, O'Brien SJ, Smith MW Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000, 97:14467-14472.
221. Yee LJ, Tang J, DGibson AW, Kimberly R, van Leeuwen DJ, Kaslow RA Interleukin-10 (IL-10) polymorphisms as predictors of sustained response in anti-viral therapy. Hepatology 2001, in press.
222. Foster CB, Lehmbecher T, Samuels S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000, 96:2562-2567.
223. Nakayama EE, Hoshino Y, Xin X, Liu H, Goto M, Watanabe N, Taguchi H, Hitani A, Kawana-Tachikawa A, Fukushima M, Yamada K, Sugiura W, Oka SI, Ajisawa A, Sato H, Takebe Y, Nakamura T, Nagai Y, Iwamoto A, Shioda T Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 2000, 74:5452-5459.
224. Witkin SS, Linhares IM, Gerber S, Caetano ME, Segurado AC Interleukin-1 receptor antagonist gene polymorphism and circulating levels of human immunodeficiency virus type 1 RNA in Brazilian women. J Virol 2001, 75:6242-6244.
225. Maas J, de Roda Husman AM, Brouwer M, Krol A, Coutinho R, Keet I, van Leeuwen R, Schuitemaker H Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. AIDS 1998, 12:2275-2280.
226. Boniotto M, Crovella S, Pirulli D, Scarlatti G, Spano A, Vatta L, Zezlina S, Tovo PA, Palomba E, Amoroso A Polymorphisms in the MBL2 promoter correlated with risk of HIV-1 vertical transmission and AIDS progression. Genes Immun 2000, 1:346-348.
227. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chavel J-P, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel A, Vernazza P, Eap CB, Telenti A, for the Swiss HIV Cohort Study Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359:30-36.
228. Dorak MT, Tang J, Tang S, Coutinho R, Goedert J, Detels R, Kaslow RA Association of HLA-B22 with increased plasma HIV-1 RNA concentration and accelerated disease progression to AIDS in Caucasian cohorts. 9th Conference on Retroviruses and Opportunistic Infections 2002.